News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week In Review: Beijing's BeiGene (BGNE) Raises $185 Million For Clinical Trial Program



11/28/2016 10:46:44 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
BeiGene completed a $200 secondary offering (including $15 million from selling shareholders) that will support global clinical trials of four novel drugs; Taikang Insurance paid $169 million to acquire 26% of China hospital operator Harmonicare; Shenzhen Hepalink invested $36.5 million in Kymab, a British novel mAb company; Beijing Tinavi Medical paid $1.5 million for China rights to spinal implants from France's Spineway; WuXi Biologics signed an MOU to create a manufacturing partnership with Prima Biomed of Australia for Prima's oncology drug candidate; Elanix Biotech of Germany and Oxford MEStar announced a LOI for a JV to market Elanix's GynRepair in China; and Yisheng Biopharma of Beijing completed a Phase I trial of its novel PIKA hepatitis B vaccine.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES